Back to top
more

Blueprint Medicines (BPMC)

(Real Time Quote from BATS)

$86.65 USD

86.65
312,488

+0.35 (0.41%)

Updated Sep 17, 2024 02:02 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (79 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Blueprint Medicines (BPMC) Q4 Loss Narrows, Revenues Top Mark

by Zacks Equity Research

Blueprint Medicines (BPMC) impresses investors with fourth-quarter earnings and revenue beat.

Deciphera's NDA for GIST Drug Gets Priority Review From FDA

by Zacks Equity Research

The FDA accepts Deciphera's (DCPH) NDA for ripretinib and grants a priority review to the same for the treatment of advanced gastrointestinal stromal tumors.

Blueprint Medicines' NDA for Avapritinib Gets Extended Review

by Zacks Equity Research

FDA extends review period for Blueprint Medicines' (BPMC) NDA seeking accelerated approval for avapritinib in fourth-line gastrointestinal stromal tumors by three months.

Lilly's NDA for Selpercatinib Gets FDA's Priority Review

by Zacks Equity Research

Lilly's (LLY) NDA for oral RET inhibitor selpercatinib gains the FDA priority review status for RET-altered lung and thyroid cancers.

Blueprint Medicines' Ayvakit Gets FDA Nod for Rare Cancer

by Zacks Equity Research

Blueprint Medicines (BPMC) gets its maiden FDA approval for its lead candidate Ayvakit to treat adult patients with PDGFRA Exon 18 mutant gastrointestinal stromal tumor (GIST).

Blueprint Medicines Posts Data From NSCLC Study on Pralsetinib

by Zacks Equity Research

Blueprint Medicines (BPMC) posts top-line data from phase I/II study on pralsetinib to treat previously treated patients with RET-fusion NSCLC. Also, it initiates the rolling NDA submission to FDA.

Blueprint Medicines Initiates Dosing in Liver Cancer Study

by Zacks Equity Research

Blueprint Medicines (BPMC) and partner CStone begin dosing in the phase Ib/II study on fisogatinib and CS1001 combo for treating patients with locally advanced/metastatic hepatocellular carcinoma.

Blueprint Medicines (BPMC) Up More Than 30% YTD: Here's Why

by Zacks Equity Research

Blueprint Medicines' (BPMC) NDA for avapritinib to treat PDGFRA Exon 18 mutant gastrointestinal stromal tumors (GIST) and fourth-line GIST is under FDA review. Other pipeline candidates also advance.

Blueprint's (BPMC) Systemic Mastocytosis Study Data Impresses

by Zacks Equity Research

Blueprint Medicines (BPMC) posts favorable initial data from the part 1 of phase II PIONEER study on avapritinib for the treatment of patients with indolent systemic mastocytosis. Stock rises.

Why Is Blueprint Medicines (BPMC) Up 1.4% Since Last Earnings Report?

by Zacks Equity Research

Blueprint Medicines (BPMC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Blueprint Medicines (BPMC) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Blueprint Medicines (BPMC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Blueprint Medicines (BPMC) Q3 Earnings & Sales Top Estimates

by Zacks Equity Research

Blueprint Medicines' (BPMC) loss is narrower than estimated in the third quarter with revenues also beating the mark. Shares rise.

Blueprint Medicines (BPMC) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Blueprint Medicines (BPMC) delivered earnings and revenue surprises of 11.87% and 148.01%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Blueprint Medicines' Avapritinib Grows to Curb Revenue Reliance

by Zacks Equity Research

The NDA for Blueprint Medicines' (BPMC) lead candidate avapritinib is currently under review in the United States. Heavy reliance on partners for collaboration revenues remains a concern.

Lilly's RET Inhibitor Shrinks Tumors in Lung Cancer Study

by Zacks Equity Research

Lilly (LLY) presents data from the LIBRETTO-001 study on selpercatinib for the treatment of RET fusion-positive non-small cell lung cancer. The candidate as a monotherapy attains 68% ORR.

Why Is Blueprint Medicines (BPMC) Down 18.3% Since Last Earnings Report?

by Zacks Equity Research

Blueprint Medicines (BPMC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Blueprint Medicines (BPMC) Q2 Loss Widens, Sales Top Mark

by Zacks Equity Research

Blueprint Medicines (BPMC) suffers wider-than-expected loss in the second quarter while sales beat estimates.

Blueprint Medicines (BPMC) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Blueprint Medicines (BPMC) delivered earnings and revenue surprises of -6.25% and 80.37%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

The Zacks Analyst Blog Highlights: Incyte, Blueprint Medicines, Verastem and uniQure

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Incyte, Blueprint Medicines, Verastem and uniQure

Cancer/Gene Therapy Biotechs in Focus After Pfizer-Array Deal

by Zacks Equity Research

A few biotechs focused on oncology or gene therapies are potential acquisition targets following the announcement by Pfizer to acquire Array BioPharma.

Blueprint Medicines (BPMC) Up 7.3% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Blueprint Medicines (BPMC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Blueprint Medicines to File NDA for Avapritinib With FDA

by Zacks Equity Research

Blueprint Medicines' (BPMC) excessive confidence in partners for revenue recognition is still a huge cause for concern.

Blueprint Medicines' NDA for Avapritinib on Track for GIST

by Zacks Equity Research

Blueprint Medicines (BPMC) reports data on avapritinib from NAVIGATOR study for treating patients with PDGFRA Exon 18 mutant GIST and the fourth-line GIST.

Blueprint Medicines (BPMC) Q1 Earnings & Sales Lag Estimates

by Zacks Equity Research

Blueprint Medicines (BPMC) posts wider-than-expected loss in first-quarter while sales miss estimates.

    Blueprint Medicines (BPMC) Reports Q1 Loss, Misses Revenue Estimates

    by Zacks Equity Research

    Blueprint Medicines (BPMC) delivered earnings and revenue surprises of -8.20% and -75.67%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?